Introduction Because of the high mortality of invasive fungal infections (IFIs), appropriate
exposure to antifungals appears to be crucial for therapeutic efficacy and safety. Materials …

Posaconazole is typically used for preventing invasive yeast and mold infections such as
invasive aspergillosis in high-risk immunocompromised patients. The oral suspension was …

Abstract The European Society for Clinical Microbiology and Infectious Diseases, the
European Confederation of Medical Mycology and the European Respiratory Society Joint …

Posaconazole is a second-generation triazole agent with a potent and broad antifungal
activity. In addition to the oral suspension, a delayed-release tablet and intravenous …

Posaconazole, a fluorinated triazole antifungal drug, is approved by the US Food and Drug
Administration (FDA) for (1) prophylaxis against Aspergillus and Candida infections in …

Triazoles represent an important class of antifungal drugs in the prophylaxis and treatment
of invasive fungal disease in pediatric patients. Understanding the pharmacokinetics of …

The syndromes of mineralocorticoid excess describe a heterogeneous group of clinical
manifestations leading to endocrine hypertension, typically either through direct activation of …

Second-generation triazoles were developed in response to the quest for more efficacious
and safer therapeutic options for the treatment of severe systemic aspergillosis and …

Abstract Exophiala dermatitidis (E. dermatitidis), which causes skin or respiratory disease, is
occasionally fatal in immunocompromised patients. Here, we report the unique antifungal …

ABSTRACT Introduction Invasive fungal infections (IFIs) are associated with a high morbidity
and mortality and their incidence is rising. Posaconazole is a triazole antifungal drug that …